What Does 'Clean' Mean When Equipment Status and Physical Condition Disagree?

An FDA warning letter to Aspen Biopharma Labs Private Limited records manufacturing equipment labelled "Cleaned" that still carried liquid with a floating substance on product-contact surfaces. The gap between a status tag and physical reality is a consequential failure in cleaning validation.

A label can be wrong — and when it is, the whole control strategy built on top of it collapses.

What happened

The Warning Letter identifies Aspen Biopharma Labs Private Limited (FEI 3012796281), Lalgadi Malakpet Village, Rangareddy, Hyderabad, Telangana, India, as recipient of MARCS-CMS 698665, Warning Letter 320-25-50, issued 5 March 2025 by FDA's Center for Drug Evaluation and Research. It follows an inspection of the firm's API facility from 16 to 21 September 2024.

FDA's first cited deviation concerns building and facility design — not established to minimise contamination and facilitate appropriate cleaning, maintenance and operations. The cleaning finding follows from that foundation.

On cleaning validation, the Warning Letter states that the firm "lacked cleaning validation studies that demonstrate your cleaning procedures are adequate." Sharper still: the firm had itself identified the need in an internal deviation report, yet investigators found none in place. That is not an oversight — it is an identified gap never closed.

The most concrete observation belongs on a training slide: investigators "observed manufacturing equipment labeled 'Cleaned' that contained liquid with a (b)(4) floating substance or residue on product-contact surfaces." The "(b)(4)" is FDA's redaction; the residue was real and visible.

FDA judged the response inadequate because it "did not provide supportive documentation or your interim plans for drug production while you complete corrective and preventive actions" — the interim state stayed uncontrolled.

Further deviations concern process validation, records retrievability and stability monitoring. Consequences extended beyond the letter: FDA placed the firm's drugs on Import Alert 66-40 on 15 January 2025; the firm agreed to a voluntary recall on 16 January 2025, initiated 7 February 2025 (recall D-0261-2025, Class II).

Why it matters

Equipment status labelling is a control, and like every control it only functions if it is true. A "Cleaned" tag asserts a validated, verified state. When that assertion coexists with visible residue, the site can no longer distinguish clean from dirty equipment at the point of use — precisely when that distinction determines whether cross-contamination occurs.

With no cleaning validation studies, nothing defined what "clean" meant: no residue limits, no worst-case matrix, no sampling strategy. The label was not a verified claim — it was a convention. Equipment returning to service on a convention rather than a demonstrated state is the failure mode cleaning validation exists to prevent.

FDA's stated consequence is unambiguous: "Inadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API's quality and safety."

What is particularly interesting

The most instructive detail is chronological, not technical. The firm had already captured the need in its own deviation report. It knew — the gap was execution and closure, and FDA rejected the response for the absence of an interim control strategy, not of good intentions.

Second, the observation is visual. Investigators needed no swab result or HPLC method; the discrepancy was apparent to the eye. The cheapest detection tool remains a trained person who can challenge the label.

Third, cleaning validation does not stand alone. A facility whose design does not facilitate cleaning struggles to produce a robust process — the letter ties both findings into one causal chain.

How such a gap can realistically develop

• Status labels treated as administrative, not technical controls. Tags are applied routinely, with no verification step and no consequence for a false state.
• A known gap without an interim barrier. When validation is deferred, production continues under the old convention — the deferred risk goes unmanaged.
• Cleaning validation defined too late. Without residue limits and a worst-case rationale, "visually clean" drifts into the default acceptance criterion.
• No ownership of the equipment state at release to use. If cleaner and releaser are not clearly accountable, the label becomes nobody's assertion.
• Visual inspection without a defined procedure. Visual verification degrades without defined lighting, surface access, viewing angles and pass/fail.

Questions for our programme

• If an investigator walked our suite today, could they find equipment tagged "Cleaned" whose condition contradicts the tag? Who would we hold accountable?
• Does our equipment status system have a verification step — and a defined response when state and condition disagree?
• When cleaning validation is pending, do we have a written interim control strategy governing production, or do we simply continue?
• Was every item in our internal deviation reports closed with documented evidence, or are some still open while production continues?
• Is our visual inspection procedure reproducible — lighting, surface access, viewing angles, duration, acceptance definition?
• Does our facility design actually facilitate cleaning, or are we asking a procedure to compensate for surfaces that cannot be cleaned reproducibly?

Wider context

Aspen Biopharma Labs Private Limited is an Indian API manufacturer in Hyderabad — not Aspen Pharmacare (South Africa); identity is fixed by FEI number, address and named recipient. The letter sits within a cluster of 2025 warning letters to India-based API manufacturers, including Jagsonpal Pharmaceuticals and Tyche Industries in February 2025. The lesson for practitioners: cleaning validation is judged not by the validation report but by the state of the equipment when investigators open the door.

Sources

• FDA Warning Letter, Aspen Biopharma Labs Private Limited, MARCS-CMS 698665 / 320-25-50, 5 March 2025 — primary source (fda.gov page and index snapshot).
• FiercePharma, "India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems," 26 March 2025.
• Pharmaceutical Technology, "FDA Issues Warning Letter to Aspen Biopharma Labs for API Manufacturing Deviations," 27 March 2025.
• Qvents, "FDA Issues Warning Letter to Aspen Biopharma's API Facility in Hyderabad."
• FDA recall record D-0261-2025 (Class II, initiated 7 February 2025).